摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trans-4,6,6a,7,9,10a-hexahydro-10a-methyl-1-(2,4,6-triisopropylphenylsulfonyl)-indolo[3,4-gh][1.4]benzoxazin-8-one

中文名称
——
中文别名
——
英文名称
trans-4,6,6a,7,9,10a-hexahydro-10a-methyl-1-(2,4,6-triisopropylphenylsulfonyl)-indolo[3,4-gh][1.4]benzoxazin-8-one
英文别名
(2R,7R)-2-methyl-15-[2,4,6-tri(propan-2-yl)phenyl]sulfonyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),9,12(16),13-tetraen-5-one
trans-4,6,6a,7,9,10a-hexahydro-10a-methyl-1-(2,4,6-triisopropylphenylsulfonyl)-indolo[3,4-gh][1.4]benzoxazin-8-one化学式
CAS
——
化学式
C29H36N2O4S
mdl
——
分子量
508.682
InChiKey
PVKUMMNRYJJOQX-GIGWZHCTSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.3
  • 重原子数:
    36
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.48
  • 拓扑面积:
    96.6
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Tetracyclic morpholine derivatives and their use or analgesics
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP0610793A1
    公开(公告)日:1994-08-17
    A compound represented by the formula wherein X is hydrogen or a substituent; R¹ is an optionally substituted hydrocarbon residue; R² and R³ are respectively hydrogen or a substituent; and ​-----¯shows a single bond or a double bond, or a pharmacologically acceptable acid addition salt thereof, has an analgesic action and is useful as a medicine.
    由以下式子表示的化合物 其中 X 是氢或取代基;R¹ 是任选取代的烃残基;R² 和 R³ 分别是氢或取代基;-----¯示单键或双键,或其药理学上可接受的酸加成盐,具有镇痛作用,可用作药物。
  • US5466689A
    申请人:——
    公开号:US5466689A
    公开(公告)日:1995-11-14
查看更多

同类化合物

伏高利特 6-乙基-9-氧杂麦角灵 (6aR,10aR)-4,7-二甲基-4,6a,7,8,9,10a-六氢-6H-吲哚并[3,4-gh][1,4]苯并噁嗪乙二酸酯 Trans-7-[2-(4-benzylpiperazin-1-yl)-1-oxoethyl]-4,6,6a,8,9,10a-hexahydro-10a-methyl-4-(2,4,6-triisopropylphenylsulfonyl)-7H-indolo[3,4-gh][1.4]benzoxazine trans-7-chloroacetyl-4,6,6a,8,9,10a-hexahydro-10a-methyl-1-(2,4,6-triisopropylphenylsulfonyl)-7H-indolo[3,4-gh][1.4]benzoxazine trans-4,6,6a,7,9,10a-hexahydro-10a-methyl-1-(2,4,6-triisopropylphenylsulfonyl)-indolo[3,4-gh][1.4]benzoxazin-8-one trans-4,6,6a,8,9,10a-hexahydro-10a-methyl-1-(2,4,6-triisopropylphenylsulfonyl)-7H-indolo[3,4-gh][1.4]benzoxazine 4,6,6a,8,9,10a-hexahydro-10a-methylindolo[3,4-gh][1.4]benzoxazine 4,6a,7,8,9,10a-Hexahydro-6H-indolo[3,4-gh][1,4]benzoxazine--hydrogen chloride (1/1) 7H-Indolo(3,4-gh)(1,4)benzoxazine, 4,5,5a,6,6a,8,9,10a-octahydro-7-propyl-, (+-)-, (5a-RS(5a-alpha,6a-beta,10a-alpha))- Oxalic acid--5-bromo-7-methyl-4,6a,7,8,9,10a-hexahydro-6H-indolo[3,4-gh][1,4]benzoxazine (1/1) 7-Propyl-4,6a,7,8,9,10a-hexahydro-6H-indolo[3,4-gh][1,4]benzoxazine--hydrogen chloride (1/1) Paspaclavin 7-Methyl-4,6a,7,8,9,10a-hexahydro-6H-indolo[3,4-gh][1,4]benzoxazine--hydrogen chloride (1/1) trans-4,6,6a,8,9,10a-hexahydro-7-n-butyl-7H-indolo-[3,4 gh]-[1,4]-benzoxazine trans-4,6,6a,8,9,10a-Hexahydro-7H-indolo-[3,4-gh]-[1,4]-benzoxazine 9-Oxaergoline, 2-bromo-6-propyl-, monohydrochloride, (+-)- 4,6,6a,8,9,10a-Hexahydro-10a-methyl-7-(2-phenoxyethyl)-7H-indolo[3,4-gh][1.4]benzoxazine (6aRS,10aRS)-4,6,6a,8,9,10a-hexahydro-7H-indolo<3,4-gh><1,4>benzoxazine 6-Methyl-4-(methylsulfanylmethyl)-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene (2S,7S)-6-ethyl-15-methoxy-2-methyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),9,12(16),13-tetraene 10-bromo-6-propyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene;hydron;chloride (2R,7R)-6,11-dimethyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene (2R,7R)-10-bromo-6-propyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene 5,6-Dimethyl-3-prop-1-en-2-yl-4-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene